ALTAPURE™ technology platform is based on the purification and separation techniques of High Performance Liquid Chromatography (HPLC). It demonstrates stable, highly effective, accurate, and excellent application value in the field of biological molecule acquirement and R&D of special drug for human and vet use, etc. This platform is the integrity of the world’s leading materials and processes, possessing a complete whole set of intellectual property, providing reliable services for the R&D of medical health products.
To gain the competitive edge, besides focusing on biological pharmacy, such as oxygen carrier Haemoglobin, nutrition proteins, amino acids, antibodies, and peptides, etc., Redpharm is also devoted into the field of ‘POCT immediate diagnosis’ , ‘ARIA’, ‘CRO/CMO Service’, etc., seeking to occupy the leading position on more segment markets.
It has been 26 years ever since the ALTAPURE™ technology platform was founded. After over twenty years’ continuous updating and optimization, abundant experiences and resources have been accumulated in the field of liquid chromatography purification and biological molecule acquirement, etc. Many patents have been obtained by the year 2017.
Redpharm (Beijing) biopharmaceutical Institute Co., Ltd is an independent research center which is the integrity of experiment, scientific research, and training. The laboratory of the research center is equipped with international top instrumentations for R&D of biological pharmacy. The construction of GMP (US and Europe) compliant facility for pilot manufacturing is also in active preparation under the guidance of our US team. We plan to develop innovative biological products that are in line with national conditions of China, and that have independent intellectual property rights, through technology transfer and local R&D.
The R&D production base of Redpharm (Qingdao) locates in Qingdao ‘Sino-German Ecopark’ where the international top companies converge. This base aims at R&D and production of high-end biological products. Phase I project covers an area of 100 mu, the investment of which is up to 160 million dollars. It will be designed and constructed as an integrated base of production, training, and research for biological products, represented by oxygen carrier Haemoglobin.